Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $11.25 Average Target Price from Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $11.25.

A number of equities analysts have recently weighed in on ASMB shares. SVB Leerink dropped their price target on shares of Assembly Biosciences from $8.00 to $7.00 and set a “market perform” rating on the stock in a research note on Monday, May 10th. Robert W. Baird restated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, February 28th. Mizuho reiterated a “buy” rating and issued a $13.00 target price on shares of Assembly Biosciences in a research note on Tuesday, May 11th. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, May 11th. Finally, Truist dropped their price target on shares of Assembly Biosciences from $45.00 to $15.00 in a research report on Tuesday, March 2nd.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its stake in shares of Assembly Biosciences by 11.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 20,676 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 2,114 shares during the last quarter. FMR LLC boosted its stake in Assembly Biosciences by 0.6% in the first quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock valued at $8,776,000 after acquiring an additional 2,680 shares during the last quarter. HRT Financial LP boosted its stake in Assembly Biosciences by 9.5% in the first quarter. HRT Financial LP now owns 31,480 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 2,735 shares during the last quarter. Rhumbline Advisers boosted its stake in Assembly Biosciences by 10.0% in the fourth quarter. Rhumbline Advisers now owns 45,903 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 4,171 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in Assembly Biosciences by 17.8% in the fourth quarter. Los Angeles Capital Management LLC now owns 28,290 shares of the biopharmaceutical company’s stock valued at $171,000 after acquiring an additional 4,270 shares during the last quarter. 71.92% of the stock is currently owned by institutional investors and hedge funds.

ASMB opened at $4.54 on Tuesday. The firm has a market capitalization of $182.32 million, a P/E ratio of -2.62 and a beta of 0.34. Assembly Biosciences has a 1-year low of $3.78 and a 1-year high of $27.84. The business has a 50 day moving average price of $4.14.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Wednesday, May 5th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.10. Assembly Biosciences had a negative return on equity of 24.46% and a negative net margin of 78.57%. On average, analysts forecast that Assembly Biosciences will post -2.76 EPS for the current year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV.

Read More: Options Trading – Understanding Strike Price

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.